HIV pharmacogenomics: Closer to personalized therapy?

American Journal of PharmacoGenomics

Volumn 4, Issue 3, 2004, Pages 141-150

  Payne, Deborah A ^a   Bryant, Barbara J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALUVIRAN; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

AMNESIA; ANOREXIA; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CONFUSION; COUGHING; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; DYSPNEA; FEVER; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEADACHE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPOGLYCEMIA; INSOMNIA; LIPODYSTROPHY; LIVER DYSFUNCTION; MITOCHONDRION; NEPHROLITHIASIS; NEPHROTOXICITY; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RACE DIFFERENCE; RASH; REVIEW; SEX DIFFERENCE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STOMATITIS; TASTE DISORDER; VIRUS GENOME; VOMITING;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENETIC MARKERS; HIV INFECTIONS; HUMANS; PHARMACOGENETICS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 3042747087     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200404030-00001     Document Type: Review

References (103)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
2. Bean P. HIV's pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics [letter]. Am Clin Lab 2000; 19: 12
3. Pirmohamed M, Back DJ. The pharmacogenomics of HIV therapy. Pharmacogenomics J 2001; 1: 243-53
4. de Montgolfier S, Moutel G, Duchange N, et al. Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients. Pharmacogenetics 2002; 12: 667-75
5. Telenti A, Aubert V, Spertini F. Individualising HIV treatment- pharmacogenetics and immunogenetics. Lancet 2002; 359: 722-3
6. McNeil AJ. Bayes estimates for immunological progression rates in HIV disease. Stat Med 1997; 16: 2555-72
7. Kroner BL, Goedert JJ, Blattner WA, et al. Concordance of human leukocyte antigen haplotype-sharing, CD4 decline and AIDS in hemophilic siblings: Multicenter Hemophilia Cohort and Hemophilia Growth and Development Studies. AIDS 1995; 9: 275-80
8. McKinnon EJ, James IR, John M, et al. Viral load detectability profiles for fflv infection. Stat Med 2003; 22: 385-96
9. Gulick RM. New antiretroviral drugs. Clin Microbiol Infect 2003; 9: 186-93
10. Bebenek K, Abbotts J, Roberts JD, et al. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J Biol Chem 1989; 264: 16948-56
11. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from fflV-1. Science 1988; 242: 1171-3
12. Blaise P, Clevenbergh P, Vaira D, et al. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin Belg 2002; 57: 191-201
13. Mallol S. Resistance and other factors involved in therapy failure. Antivir Ther 2001; 6 Suppl. 2: 21-7
14. Alexander L, Weiskopf E, Greenough TC, et al. Unusual polymorphismsin human immunodeficiency virus type I associated with nonprogressive infection. J Virol 2000; 74: 4361-76
15. Ravela J, Betts BJ, Brun-Vezinet F, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003 May 1; 33 (1): 8-14
16. Sturmer M, Doerr HW, Staszewski S, et al. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 2003 Jun; 8 (3): 239-44
17. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6: 9-20
18. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-23
19. Nolan D, John M, Mallal S. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir Ther 2001; 6: 145-60
20. Nolan D, Mallal S. Getting to the HAART of insulin resistance. AIDS 2001; 15: 2037-41
21. Nolan D, Mallal S. Effects of sex and race on lipodystrophy pathogenesis. J HIV Ther 2001; 6: 32-6
22. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15: 1275-80
23. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002; 15: 23-9
24. Fridland A, Connelly MC, Robbins BL. Cellular factors for resistance against antiretroviral agents. Antivir Ther 2000; 5: 181-5
25. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-6
26. Just JJ. Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: a review of the literature examining associations with HLA [published erratum appears in Hum Immunol 1996 Jan; 45 (1): 78]. Hum Immunol 1995; 44: 156-69
27. Just JJ. Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome: a review of the literature examining associations with HLA [published erratum appears in Hum Immunol 1996 Jan; 45 (1): 78]. Hum Immunol 1995; 44: 156-69
28. Just JJ, Abrams E, Louie LG, et al. Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1. J Pediatr 1995; 127: 544-9
29. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-38
30. Martin AM, Hammond E, Nolan D, et al. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet 2003; 72: 549-60
31. Hammond EL, Sayer D, Nolan D, et al. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003; 27: 97-110
32. Mascolini M. Sublime versus simple side effect stories (or, forget the adiponectin, just stop smoking). 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2003 Jul 8-11; Paris. IAPAC Monthly 2003 Sep; 9 (10): 242-8, 252-61
33. Re MC, Bon I, Monari P, et al. Drug failure during HIV-1 treatment: new perspectives in monitoring drug resistance. New Microbiol 2003 Oct; 26 (4): 405-13
34. Sandstrom E, Uhnoo I, Ahlqvist-Rastad J, et al., for the Swedish Consensus Group. Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations. Scand J Infect Dis 2003; 35 (3): 155-67
35. Lewis W. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res 2003; 58: 189-97
36. Tang J, Allen S, Karita E, et al. New TAP2 polymorphisms in Africans. Tissue Antigens 1998; 51: 556-62
37. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-21
38. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002; 25: 1391-400
39. Brumme ZL, Dong WW, Chan KJ, et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003; 17: 201-8
40. Andrade A, Flexner C. HIV-related drug metabolism and cytochrome P450 enzymes. AIDS Clin Care 2000; 12: 91-5
41. Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000; 10: 705-13
42. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68: 82-91
43. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6: 2012-20
44. Hirota N, Ito K, Iwatsubo T, et al. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 2001; 22: 53-71
45. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121-32
46. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression: Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1991; 211: 959-65
47. Libert F, Cochaux P, Beckman G, et al. The delta ccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998; 7: 399-406
48. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282: 1907-11
49. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998; 62: 1507-15
50. An P, Martin MP, Nelson GW, et al. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 2000; 14: 2117-22
51. Martinson JJ, Hong L, Karanicolas R, et al. Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype. AIDS 2000; 14: 483-9
52. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000; 14: 2671-8
53. McDermott DH, Colla JS, Kleeberger CA, et al. Genetic polymorphism in CX3CR1 and risk of HIV disease [letter]. Science 2000; 290: 2031
54. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1 alpha: impact on the epidemiology of the fflV-1 pandemic. Proc Natl Acad Sci U S A 2001; 98: 5199-204
55. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-641, and SDF-1 3 A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001; 135: 782-95
56. Kageyama S, Mimaya J, Yamada K, et al. Polymorphism of CCR5 affecting HIV disease progression in the Japanese population. AIDS Res Hum Retroviruses 2001; 17: 991-5
57. Klitz W, Brautbar C, Schito AM, et al. Evolution of the CCR5 Delta32 mutation based on haplotype variation in Jewish and Northern European population samples. Hum Immunol 2001; 62: 530-8
58. Mangano A, Gonzalez E, Dhanda R, et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001; 183: 1574-85
59. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97: 1925-8
60. Ometto L, Bertorelle R, Mainardi M, et al. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J Infect Dis 2001; 183: 814-8
61. Ramaley PA, French N, Kaleebu P, et al. HIV in Africa (communication arising): chemokine-receptor genes and AIDS risk [letter]. Nature 2002; 417: 140
62. Tang J, Shelton B, Makhatadze NJ, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76: 662-72
63. Tang J, Wilson CM, Schaen M, et al. CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18: 403-12
64. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54: 535-51
65. Pichler WJ. Drug allergy. Curr Opin Allergy Clin Immunol 2001; 1: 285-6
66. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-2
67. HLA haplotype and HIV infection [letter[. Lancet 1988; 11: 342-3
68. Steel CM, Ludlam CA, Beatson D, et al. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988; I: 1185-8
69. Cameron PU, Mallal SA, French MA, et al. Major histocompatibility complex genes influence the outcome of HIV infection: ancestral haplotypes with C4 null alleles explain diverse HLA associations. Hum Immunol 1990; 29: 282-95
70. Kaplan C, Muller JY, Doinel C, et al. HLA-associated susceptibility to acquired immune deficiency syndrome in HIV-1-seropositive subjects. Hum Hered 1990; 40: 290-8
71. Kaslow RA, Duquesnoy R, VanRaden M, et al. Al, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection: a report from the Multicenter AIDS Cohort Study. Lancet 1990; 335: 927-30
72. Mallal S, Cameron PU, French MA, et al. MHC genes and HIV infection. Lancet 1990; 335: 1591-2
73. Louie LG, Newman B, King MC. Influence of host genotype on progression to AIDS among MTV-infected men. J Acquir Immune Defic Syndr 1991; 4:814-8
74. Puppo F, Ruzzenenti R, Brenci S, et al. Major histocompatibility gene products and human immunodeficiency virus infection. J Lab Clin Med 1991; 117: 91-100
75. Donald JA, Rudman K, Cooper DW, et al. Progression of HIV-related disease is associated with HLA DQ and DR alleles defined by restriction fragment length polymorphisms. Tissue Antigens 1992; 39: 241-8
76. Leelayuwat C, Zhang WJ, Abraham LJ, et al. Differences in the central major histocompatibility complex between humans and chimpanzees: implications for development of autoimmunity and acquired immune deficiency syndrome. Hum Immunol 1993; 38: 30-41
77. Peixinho ZF, Mendes NF. HLA antigens and resistance to HIV. J Clin Lab Anal 1994; 8: 456-8
78. Brackin MN, Lewis RE, Brackin BT, et al. Progression of HIV infection is associated with HLA-DQ antigens in Caucasians and African Americans. Pathobiology 1995; 63: 22-41
79. Achord AP, Lewis RE, Brackin MN, et al. HLA-DQB1 markers associated with human immunodeficiency virus type 1 disease progression. Pathobiology 1997; 65: 210-5
80. Candore G, Romano GC, D'Anna C, et al. Biological basis of the HLA-B8, DR3-associated progression of acquired immune deficiency syndrome. Pathobiology 1998; 66: 33-7
81. Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (Al, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999; 167: 257-74
82. Price P, Keane NM, Stone SF, et al. MHC haplotypes affect the expression of opportunistic infections in HIV patients. Hum Immunol 2001; 62: 157-64
83. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32
84. Moore CB, John M, James IR. et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296: 1439-43
85. Tang J, Tang S, Lobashevsky E, et al. Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. J Virol 2002; 76: 8276-84
86. Evans DT, Knapp LA, Jing P, et al. Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV. Immunol Lett 1999; 66: 53-9
87. Faure S, Meyer L, Costagliola D, et al. Rapid progression to AIDS in HTV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000; 287: 2274-7
88. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003; 17: 121-3
89. Modi WS, O'Brien TR, Vlahov D, et al. Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression. Immunogenetics 2003; 55 (3): 157-64
90. Pugliese A, Gennero L, Pescarmona GP, et al. Serum citrate levels, haptoglobin haplotypes and transferrin receptor (CD71) in patients with HIV-1 infection. Infection 2002; 30: 86-9
91. Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HTV-1 patients who experienced immune restoration diseases. AIDS 2002; 16: 2043-7
92. Kobayashi N, Nakamura HT, Goto M, et al. Polymorphisms and haplotypes of the CD209L gene and their association with the clinical courses of HIV-positive Japanese patients. Jpn J Infect Dis 2002; 55: 131-3
93. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A 2002; 99: 13795-800
94. Bean P. Alcohol use and HIV pharmacotherapy [letter]. Am Clin Lab 2000; 19: 16
95. Kresina TF, Flexner CW, Sinclair J, et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 2002; 18: 757-70
96. Indiana University Department of Medicine. Drug interactions: cytochrome P450 system [online]. Available from URL: http://medicine.iupui.edu/flockhart/ [Accessed 2004 Feb 26]
97. Morgan ET. Down-regulation of multiple cytochrome P450 gene products by inflammatory mediators in vivo: independence from the hypothalamo-pituitary axis. Biochem Pharmacol 1993; 45: 415-9
98. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 2001; 29: 207-12
99. Mathis AS, DiRenzo T, Friedman GS, et al. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. Transplantation 2001; 71: 1069-75
100. Siegel K, Karus D, Schrimshaw EW. Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care 2000; 12: 423-34
101. Boxwell DE. SBA. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs) [abstract 1284]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA)
102. Singh KK, Barroga CF, Hughes MD, et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis 2003 Nov 15; 188 (10): 1461-72. Epub 2003 Nov 18
103. Agrawal L, Lu X, Qingwen J, et al. Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol 2004 Mar; 78 (5): 2277-87